Supernus Pharma (SUPN) Announces SPN-812 Phase 2b Met Primary Endpoint as ADHD Treatment
Tweet Send to a Friend
Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN) announced positive topline results from its Phase IIb dose-ranging clinical trial of SPN-812 in children ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
